Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

MBCC: Bridging Bench to Bedside: The Potential for Immunotherapeutic Strategies in Breast Cancer

MBCC: Bridging Bench to Bedside: The Potential for Immunotherapeutic Strategies in Breast Cancer


Date: Sunday, March 11, 2018

Time: 7:00 AM – 8:30 AM
Breakfast and registration: 6:30 AM – 7:00 AM

Location:
Fontainebleau Miami Beach
Meeting Room: Fontaine
4441 Collins Avenue
Miami Beach, FL 33140

Overview

We are pleased to announce the satellite symposium, Bridging Bench to Bedside: The Potential for Immunotherapeutic Strategies in Breast Cancer, to be held at the 35th Miami Breast Cancer Conference®. Traditionally, breast cancer has not been seen as an immune-sensitive disease. Over the past 20 years, translational research has taught us that breast cancer includes large numbers of different molecular entities, and that some of them are clearly “immune-related” subtypes. Listen to key experts discuss how an understanding of the basic immunology of breast cancer, neoantigens, and breast cancer’s various subtypes provide a foundation for evaluating the emerging data for patients with hormone receptor‒positive (HR+)/HER2-, HER2+, and triple-negative breast cancer. Enhance your clinicals skills by understanding the rationale for use of immunotherapies in the management of these most difficult-to-treat tumors, and assess how emerging efficacy and safety data should be placed into the context of evolving treatment paradigms.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

After successful completion of this educational activity, participants should be better prepared to:

  • Evaluate the latest data regarding mechanisms of immunotherapeutic strategies as they apply to breast malignancies and emerging biomarkers guiding the optimal selection of patients
  • Review efficacy and safety data for immunotherapeutic approaches across multiple breast malignancies and patient types
  • Describe key clinical issues regarding the application of immune checkpoint inhibitors and summarize ongoing associated trials
  • Determine the occurrence of and methods to mitigate the impact of immune-related adverse events based on recent clinical trial evidence

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Program Chair

Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
San Francisco, CA








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By